| Biomarker ID | 393 |
| PMID | 18974881 |
| Year | 2008 |
| Biomarker | Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Benign Vs Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 41 patients were diagnosed with CaP. 66 specimens were recieved out of which 44 were benign-Cancerous pairs from the same patient. 35 were classifed as benign and 31 were classified as Prostate Cancer. |
| Senstivity | 81±6% |
| Specificity | 78 ± 7% |
| AUC | NA |
| Accuracy | 80±5% |
| Level Of Significance | Clusterin: p<0.01 |
| Method Used | RT- qPCR |
| Clinical | No |
| Remarks | 10 fold cross validation was applied. And Nearest Neighor technique was applied to the signature. Individually only Clusterin showed significant differential expression, but together as a signature it has good predictive power |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |